(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -7.30%818.48B | -7.83%544.52B | -2.56%265.01B | 9.45%1.26T | 4.09%882.92B | 5.38%590.77B | 2.04%271.97B | 7.55%1.15T | 10.45%848.18B | 12.52%560.59B |
Special items of operating revenue | 12.54%1.8B | ---- | -2.56%634.19M | ---- | -14.16%1.6B | ---- | 16.13%650.83M | ---- | -18.54%1.87B | ---- |
Operating income | -7.26%820.28B | -7.83%544.52B | -2.56%265.65B | 9.45%1.26T | 4.05%884.52B | 5.38%590.77B | 2.07%272.62B | 7.55%1.15T | 10.37%850.05B | 12.52%560.59B |
Cost of sales | ---- | 7.80%-497.77B | ---- | -9.11%-1.14T | ---- | -5.02%-539.86B | ---- | -7.79%-1.05T | ---- | -12.61%-514.04B |
Operating expenses | 7.00%-746.49B | 7.80%-497.77B | 2.21%-242.26B | -9.11%-1.14T | -3.81%-802.67B | -5.02%-539.86B | -2.15%-247.74B | -7.79%-1.05T | -10.82%-773.19B | -12.61%-514.04B |
Gross profit | -9.85%73.79B | -8.15%46.76B | -6.02%23.38B | 12.67%122.69B | 6.48%81.85B | 9.36%50.91B | 1.23%24.88B | 5.32%108.89B | 5.98%76.86B | 11.45%46.55B |
Selling expenses | 0.81%-4.38B | 5.15%-2.91B | 10.82%-1.35B | -8.25%-6.85B | -6.27%-4.42B | -13.30%-3.07B | -12.83%-1.51B | -6.39%-6.33B | -8.09%-4.16B | -14.13%-2.71B |
Administrative expenses | 6.53%-17.63B | 1.72%-12.9B | -4.18%-6.71B | -9.64%-28.96B | -4.90%-18.86B | -7.39%-13.13B | -4.38%-6.44B | -3.84%-26.41B | -4.54%-17.98B | 2.32%-12.23B |
Research and development expenses | 9.68%-16.09B | 10.36%-9.23B | 9.64%-3.47B | -8.14%-30B | -12.50%-17.81B | -14.60%-10.29B | 14.27%-3.84B | -12.06%-27.74B | -15.84%-15.83B | ---8.98B |
Profit from asset sales | -63.76%84.15M | ---- | -40.01%149.42M | ---- | 1,357.38%232.19M | ---- | 883.22%249.08M | ---- | -107.23%-18.47M | ---- |
Revaluation surplus | 118.59%61.62M | ---- | -83.41%-84.69M | ---- | -3.69%-331.53M | ---- | 60.29%-46.18M | ---- | -49.59%-319.74M | ---- |
-Changes in the fair value of other assets | 118.59%61.62M | ---- | -83.41%-84.69M | ---- | -3.69%-331.53M | ---- | 60.29%-46.18M | ---- | -49.59%-319.74M | ---- |
Impairment and provision | -25.00%-2.92B | 5.34%-1.76B | 39.87%-665.18M | -113.79%-7.15B | 37.04%-2.34B | -31.28%-1.86B | -30.50%-1.11B | 38.97%-3.34B | 12.68%-3.71B | -2.24%-1.41B |
-Other impairment is provision | -25.00%-2.92B | 5.34%-1.76B | 39.87%-665.18M | -113.79%-7.15B | 37.04%-2.34B | -31.28%-1.86B | -30.50%-1.11B | 38.97%-3.34B | 12.68%-3.71B | -2.24%-1.41B |
Operating interest expense | -18.74%-356.03M | ---- | -29.89%-181.29M | ---- | -66.02%-299.83M | ---- | -774.96%-139.57M | ---- | 68.01%-180.6M | ---- |
Special items of operating profit | -11.22%1.22B | -718.68%-563M | -25.65%844.91M | -101.42%-2.56B | -35.60%1.37B | -74.00%91M | 24.46%1.14B | 67.60%-1.27B | 59.90%2.13B | 104.80%350M |
Operating profit | -13.96%30.34B | -14.36%19.4B | -8.82%10.83B | 7.71%47.17B | 8.16%35.26B | 5.01%22.66B | 6.30%11.88B | 15.72%43.79B | 6.50%32.6B | 18.51%21.58B |
Financing income | ---- | 3.35%4.45B | ---- | 21.34%8.71B | ---- | 45.57%4.3B | ---- | 17.61%7.18B | ---- | 32.20%2.96B |
Financing cost | -1.75%-3.32B | -3.65%-5.74B | 9.44%-1.02B | -24.17%-11.89B | -56.34%-3.27B | -34.31%-5.54B | -16.04%-1.13B | -25.76%-9.58B | 33.69%-2.09B | -37.92%-4.12B |
Share of profits of associates | ---- | -23.96%1.66B | ---- | -1.44%4.67B | ---- | 6.63%2.19B | ---- | 24.28%4.73B | ---- | 74.55%2.05B |
Share of profit from joint venture company | ---- | 66.46%-214M | ---- | 25.19%-1.08B | ---- | -13.12%-638M | ---- | -183.43%-1.44B | ---- | -161.11%-564M |
Special items of earning before tax | 1,116.78%209.52M | ---- | 128.49%51.13M | ---- | -76.88%17.22M | ---- | -85.94%22.38M | ---- | 123.33%74.49M | ---- |
Earning before tax | -14.95%27.23B | -14.85%19.56B | -8.47%9.86B | 6.46%47.58B | 4.66%32.01B | 4.91%22.97B | 3.97%10.77B | 12.76%44.69B | 12.69%30.59B | 18.93%21.9B |
Tax | 16.30%-4.77B | 17.35%-3.89B | 3.81%-1.83B | -2.25%-9.94B | -2.55%-5.69B | 7.49%-4.71B | 7.23%-1.91B | -6.10%-9.73B | -14.17%-5.55B | -25.28%-5.09B |
After-tax profit from continuing operations | -14.66%22.46B | -14.21%15.67B | -9.47%8.03B | 7.64%37.64B | 5.13%26.32B | 8.66%18.26B | 6.74%8.87B | 14.76%34.97B | 12.36%25.04B | 17.13%16.81B |
After-tax profit from non-continuing business | --0 | ---- | ---- | ---- | --0 | ---- | ---- | ---- | --0 | ---- |
Earning after tax | -14.66%22.46B | -14.21%15.67B | -9.47%8.03B | 7.64%37.64B | 5.13%26.32B | 8.66%18.26B | 6.74%8.87B | 14.76%34.97B | 12.36%25.04B | 17.13%16.81B |
Minority profit | -18.07%1.89B | -31.36%1.39B | -44.75%545.85M | 12.45%4.15B | 13.69%2.31B | 19.61%2.03B | 37.32%987.93M | 29.52%3.69B | 24.21%2.03B | 34.90%1.69B |
Adjustment items of profit attributable to shareholders | ---- | ---- | ---- | ---- | ---- | ---- | --2K | ---- | ---- | ---- |
Profit attributable to shareholders | -14.33%20.57B | -12.07%14.28B | -5.04%7.48B | 7.07%33.48B | 4.37%24.01B | 7.44%16.24B | 3.84%7.88B | 13.23%31.27B | 11.43%23.01B | 15.43%15.12B |
Basic earnings per share | -14.13%0.784 | -12.07%0.532 | -5.25%0.289 | 8.01%1.294 | 4.82%0.913 | 9.80%0.605 | 3.74%0.305 | 15.53%1.198 | 19.15%0.871 | 21.37%0.551 |
Diluted earnings per share | -14.13%0.784 | -12.07%0.532 | -5.25%0.289 | 7.85%1.292 | 4.82%0.913 | 9.80%0.605 | 3.74%0.305 | 15.53%1.198 | 19.15%0.871 | 21.37%0.551 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
Auditor | -- | -- | -- | PricewaterhouseCoopers, PricewaterhouseCoopers Zhongtian (Special General Partnership) | -- | -- | -- | PricewaterhouseCoopers, PricewaterhouseCoopers Zhongtian (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data